Diabetes drug study reveals hidden genetic links to weight and inflammation
NCT ID NCT07120828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how two common diabetes drugs, dapagliflozin and empagliflozin, affect weight, cholesterol, and inflammation in 260 obese adults newly diagnosed with type 2 diabetes. Over six months, researchers measured changes in body weight, blood fats, and markers of oxidative stress, and also checked how a gene called CYP8B1 might influence these effects. The goal was to better understand the broader health benefits of these medications beyond blood sugar control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESE DIABETICS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Epu
Erbil, Kurdistan, 44001, Iraq
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?